The electro-mechanical window in anaesthetized guinea pigs: A new marker in screening for Torsade de Pointes risk

British Journal of Pharmacology

Volumn 166, Issue 2, 2012, Pages 689-701

  Guns, P J ^a   Johnson, D M ^a   Van Op Den Bosch, J ^a   Weltens, E ^a   Lissens, J ^a  

^a Bio Plus Safety Pharmacology   (Belgium)

Author keywords

anaesthetized; drug induced QT prolongation; E M window; electro mechanical window; guinea pig; ICH S7B; proarrhythmia; QT interval; safety pharmacology; TdP; Torsade de Pointes

Indexed keywords

AMIODARONE; CIPROFLOXACIN; DILTIAZEM; DOFETILIDE; DOMPERIDONE; HALOPERIDOL; MOXIFLOXACIN; QUINIDINE; SALBUTAMOL; TERFENADINE; THIORIDAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE MEASUREMENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE MARKER; ELECTROMECHANICAL WINDOW; GUINEA PIG; HEART RATE; HIGH RISK POPULATION; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; SYSTOLE; TORSADE DES POINTES;

ANESTHESIA; ANIMALS; BODY TEMPERATURE; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; HEART RATE; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; RISK; TORSADES DE POINTES;

EID: 84859900813     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01795.x     Document Type: Article

References (48)

1. Airaksinen J, Ikaheimo M, Kaila J, Linnaluoto M, Takkunen J, (1984). Systolic time intervals and the QT-QS2 interval in young female diabetics. Ann Clin Res 16: 188-191. (Pubitemid 15203607)
2. Ball P, (2000). Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 45: 557-559. (Pubitemid 30255632)
3. Batey AJ, Coker SJ, (2002). Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes. Br J Pharmacol 135: 1003-1012. (Pubitemid 34214460)
4. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, et al,. (2008). The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 84: 475-480.
5. Boudoulas H, Geleris P, Lewis RP, Leier CV, (1981a). Effect of increased adrenergic activity on the relationship between electrical and mechanical systole. Circulation 64: 28-33. (Pubitemid 11078885)
6. Boudoulas H, Geleris P, Lewis RP, Rittgers SE, (1981b). Linear relationship between electrical systole, mechanical systole, and heart rate. Chest 80: 613-617.
7. Boudoulas H, Sohn YH, O'Neill W, Brown R, Weissler AM, (1982). The QT greater than QS2 syndrome: a new mortality risk indicator in coronary artery disease. Am J Cardiol 50: 1229-1235. (Pubitemid 13243831)
8. Cavero I, Crumb W, (2005). ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opin Drug Saf 4: 509-530. (Pubitemid 40723724)
9. Chambers JB, Ward DE, (1987). The QT and QS2 intervals in patients with mitral leaflet prolapse. Am Heart J 114: 355-361. (Pubitemid 17131730)
10. Darpo B, (2001). Spectrum of drugs prolonging QT interval and theincidence of torsades de pointes. Eur Heart J 3: K70-K80.
11. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG, (2005). Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26: 590-597. (Pubitemid 40461101)
12. De Caprio L, Ferro G, Cuomo S, Volpe M, Artialo D, De luca N, et al,. (1984). QT/QS2 ratio as an index of autonomic tone changes. Am J Cardiol 53: 818-822. (Pubitemid 14154698)
13. DiMasi JA, Paquette C, (2004). The economics of follow-on drug research and development: trends in entry rates and the timing of development. Pharmacoeconomics 22: 1-14. (Pubitemid 39481914)
14. Drouin E, Lande G, Charpentier F, (1998). Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol 32: 1063-1067. (Pubitemid 28459600)
15. Gintant GA, (2008). Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacol Ther 119: 199-209.
16. Guns P-J, Teisman A, Van Ammel K, Towart R, Straetemans R, Bult H, et al,. (2010). Can retrospective analysis of preclinical cardiovascular safety data improve predictivity of future results? J Pharmacol Toxicol Methods 62: e29-e30.
17. Hamlin RL, Kijtawornrat A, Keene BW, Hamlin DM, (2003). QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. Toxicol Sci 76: 437-442. (Pubitemid 38035437)
18. Hauser DS, Stade M, Schmidt A, Hanauer G, (2005). Cardiovascular parameters in anaesthetized guinea pigs: a safety pharmacology screening model. J Pharmacol Toxicol Methods 52: 106-114. (Pubitemid 41008634)
19. Hoffmann P, Warner B, (2006). Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods 53: 87-105.
20. Hohnloser SH, Klingenheben T, Singh BN, (1994). Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 121: 529-535.
21. Hondeghem LM, (2006). Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol 17: 337-340. (Pubitemid 43344952)
22. Kagstrom J, Sjogren EL, Ericson AC, (2007). Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs. J Pharmacol Toxicol Methods 56: 186-193. (Pubitemid 47381504)
23. Kodama I, Kamiya K, Toyama J, (1997). Cellular electropharmacology of amiodarone. Cardiovasc Res 35: 13-29. (Pubitemid 27374736)
24. Lawrence CL, Pollard CE, Hammond TG, Valentin JP, (2005). Nonclinical proarrhythmia models: predicting Torsades de Pointes. J Pharmacol Toxicol Methods 52: 46-59. (Pubitemid 41008629)
25. Lazzara R, (1989). Amiodarone and torsade de pointes. Ann Intern Med 111: 549-551. (Pubitemid 19244552)
26. van der Linde HJ, Van Deuren B, Teisman A, Towart R, Gallacher DJ, (2008). The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correction. Br J Pharmacol 154: 1474-1481.
27. van der Linde HJ, Van Deuren B, Somers Y, Loenders B, Towart R, Gallacher DJ, (2010). The electro-mechanical window: a risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias. Br J Pharmacol 161: 1444-1454.
28. Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ, (2007). In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 577: 222-232.
29. Lu Z, Kamiya K, Opthof T, Yasui K, Kodama I, (2001). Density and kinetics of I(Kr) and I(Ks) in guinea pig and rabbit ventricular myocytes explain different efficacy of I(Ks) blockade at high heart rate in guinea pig and rabbit: implications for arrhythmogenesis in humans. Circulation 104: 951-956. (Pubitemid 32778049)
30. Magnano AR, Holleran S, Ramakrishnan R, Reiffel JA, Bloomfield DM, (2002). Autonomic nervous system influences on QT interval in normal subjects. J Am Coll Cardiol 39: 1820-1826. (Pubitemid 34595295)
31. Mattioni TA, Zheutlin TA, Sarmiento JJ, Parker M, Lesch M, Kehoe RF, (1989). Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. Ann Intern Med 111: 574-580. (Pubitemid 19244558)
32. Merot J, Charpentier F, Poirier JM, Coutris G, Weissenburger J, (1999). Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol. Cardiovasc Res 44: 303-314. (Pubitemid 29474093)
33. Ming Z, Nordin C, (1995). Terfenadine blocks time-dependent Ca2+, Na+, and K+ channels in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 26: 761-769.
34. van Opstal JM, Schoenmakers M, Verduyn SC, de Groot SH, Leunissen JD, van Der Hulst FF, et al,. (2001). Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 104: 2722-2727. (Pubitemid 33108141)
35. Patmore L, Fraser S, Mair D, Templeton A, (2000). Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. Eur J Pharmacol 406: 449-452.
36. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al,. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45. (Pubitemid 36351620)
37. Sakaguchi Y, Sugiyama A, Takao S, Akie Y, Takahara A, Hashimoto K, (2005). Halothane sensitizes the guinea-pig heart to pharmacological IKr blockade: comparison with urethane anesthesia. J Pharmacol Sci 99: 185-190. (Pubitemid 41524457)
38. Shah RR, Hondeghem LM, (2005). Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2: 758-772. (Pubitemid 40903686)
39. Tabo M, Kimura K, Ito S, (2007). Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization. J Pharmacol Toxicol Methods 55: 254-261. (Pubitemid 46436525)
40. Terrar DA, Wilson CM, Graham SG, Bryant SM, Heath BM, (2007). Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization. J Pharmacol Toxicol Methods 56: 171-185. (Pubitemid 47375123)
41. Testai L, Calderone V, Salvadori A, Breschi MC, Nieri P, Martinotti E, (2004). QT prolongation in anaesthetized guinea-pigs: an experimental approach for preliminary screening of torsadogenicity of drugs and drug candidates. J Appl Toxicol 24: 217-222. (Pubitemid 38801628)
42. Thomsen MB, Beekman JD, Attevelt NJ, Takahara A, Sugiyama A, Chiba K, et al,. (2006). No proarrhythmic properties of the antibiotics moxifloxacin or azithromycin in anaesthetized dogs with chronic-AV block. Br J Pharmacol 149: 1039-1048. (Pubitemid 44950807)
43. Van Deuren B, Van Ammel K, Somers Y, Cools F, Straetemans R, van der Linde HJ, et al,. (2009). The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research. J Pharmacol Toxicol Methods 60: 11-23.
44. Vincent GM, Jaiswal D, Timothy KW, (1991). Effects of exercise on heart rate, QT, QTc and QT/QS2 in the Romano-Ward inherited long QT syndrome. Am J Cardiol 68: 498-503.
45. Vohra J, (2007). The long QT syndrome. Heart Lung Circ 16 (Suppl. 3): S5-12. (Pubitemid 47233299)
46. Yao X, Anderson DL, Ross SA, Lang DG, Desai BZ, Cooper DC, et al,. (2008). Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br J Pharmacol 154: 1446-1456.
47. Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Kugiyama K, et al,. (2002). Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. Circ J 66: 758-762.
48. Zicha S, Moss I, Allen B, Varro A, Papp J, Dumaine R, et al,. (2003). Molecular basis of species-specific expression of repolarizing K+ currents in the heart. Am J Physiol Heart Circ Physiol 285: H1641-H1649. (Pubitemid 37169520)